key: cord-0739796-iznl970f authors: Guan, Jin-Tao; Wang, Wei-Jie; Jin, Du; Mou, Xiao-Yue; Lei, Shan-Shan; Xu, Zheng-Hao title: A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients date: 2021-08-20 journal: Ther Adv Chronic Dis DOI: 10.1177/20406223211039699 sha: 933eab7291001706bfae65d6968e4909b6472828 doc_id: 739796 cord_uid: iznl970f OBJECTIVE: This meta-analysis aims to assess the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies on COVID-19. METHODS: Relevant literatures about GM-CSF antibody treatment in COVID-19 patients were searched from the PubMed, Cochrane Library, Embase, Google scholar, and Baiduscholar databases from the COVID-19 outbreak in December 2019 until 1 January 2021. The primary outcomes included the death, intensive care unit (ICU) admission risk, ventilation requirement, and secondary infection. RESULTS: A total of 12 eligible literature involving 8979 COVID-19 patients were recruited, and they were divided into experimental group (n = 2673) and control group (n = 6306). Using a random-effect model, it is found that the GM-CSF antibody treatment was associated with a 23% decline of the risk of death [odd’s ratio (OR): 0.34, 95% confidence interval (CI): 0.21–0.56, p < 0.0001] and a 20% enhancement of ventilation (OR: 1.47, 95% CI: 1.19, 1.80, p = 0.0002). GM-CSF antibody treatment did not have a significant correlation to secondary infection and increased risk of ICU admission in COVID-19 patients, which may be attributed to the older age and the length of stay. CONCLUSIONS: Severe COVID-19 patients can benefit from GM-CSF antibodies. was conducted to investigate GM-CSF antibody treatment in COVID-19 patients. Inclusion and exclusion criteria and data collection J.G. and W.W were responsible for the literature search and data analyses. After searching for relevant literature on online databases, duplicate studies were excluded using EndNote X9; noneligible literature was further excluded by reviewing the full-text. Any disagreement was resolved by the third investigator (S. L). Briefly, literature concerning GM-CSF antibody treatment alone, or in combination with other specific treatments, of adult COVID-19 patients were included. Those studies that involved non-adult COVID-19 patients and which were without clear results were excluded. The study was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement checklist. J.G. and W.W. were responsible for searching relevant literature in the Web of Science, Embase, Pubmed, Google scholar, and other databases (Baidu scholar, CNKI). References for each piece of literature were manually reviewed. Any disagreement was solved by the third author (Z.X.). In detail, relevant literature published from 1 December 2019 year until 1 January 2021 with the following search keywords were searched: 'GM-CSF', 'CSF', 'tocilizumab', 'atlizumab', 'actemra', 'roactemra', 'kevzara', 'sylvant', 'CNTO-328', 'SARS-CoV-2', 'coronavirus', 'nCoV', 'pneumonia', 'corona-viru', '2019 nCoV', 'COVID-19', 'WuHan', 'lenzilumab', 'TJM', 'recombinant monoclonal antibodies against granulocyte macrophage colony-stimulating factor', 'monoclonal antibodies against granulocyte macrophage colony-stimulating factor', 'antibodies against granulocyte macrophage colony-stimulating factor', and 'mavrilimumab'. Study selection and data extraction J. G. and W.W were responsible for extracting data through eligible literature, including the number of recruited patients, therapeutic strategies, ventilation conditions, ICU admission risk, death number, severe case number, risks of COVID-19, length of stay, secondary infection, and severe events (e.g., sepsis, acute kidney injury, cardiac injury) etc. Assessment of study quality Study quality was assessed using the Newcastle-Ottawa Scale (NOS) 7 (Supplemental Table S1 ). Pooled estimates were presented as odds ratios (OR) and 95% confidence intrevals (CIs) and visualized by forest plots. Heterogeneity among studies was evaluated by χ 2 , I 2 , df, and Tau 2 . Negative I 2 values were set to zero. 25%, 50%, and 75% I 2 indicated a low, moderate, and high heterogeneity, respectively. Publication bias was assessed by using funnel plots and Egger's asymmetry test. Revman 5.3 was used for statistical processing. Following the searching strategy described in Figure 1 , 12,577 pieces of literature were initially identified based on the assessment of the titles and abstracts. We excluded 12,565 pieces of literature strictly conformed to the inclusion and exclusion criteria. At last, a total of 12 pieces of eligible literature were finally included in the meta-analysis. A total 12 pieces of eligible literature involving 8979 COVID-19 patients were divided into GM-CSF antibody treatment group (n = 2673) and control group (n = 6306). The baseline characteristics, including the study design (type of study), treatment methods of each group, sample sizes of each group, and NOS score of each study were shown in Table 1 . Mortality data were obtained from 8 studies involving 1,530 COVID-19 patients; of these, 301/1530 received GM-CSF antibody treatment. As shown in Figure 2 , GM-CSF antibody journals.sagepub.com/home/taj 3 treatment significantly improved the overall survival (OS) of COVID-19 than conventional treatment (OR = 0.34, 95% CI: 0.21, 0.56). The test for the overall efficacy manifested as the following: Z = 4.31 (p < 0.0001), Tau 2 = 0.10; Chi 2 = 8.98, df = 7 (p = 0.25), and I 2 = 22%. To estimate the risk of intensive care unit (ICU) admission in COVID-19 patients, we analyzed the data of 3337 COVID-19 patients from 4 studies, including 617 in the GM-CSF antibody treatment group and 2720 in the control group. In the former group, 244/617 patients were admitted for ICU admission; while 389/2720 in the control group were admitted for ICU admission. As shown in Figure 3 , the test for the overall efficacy was Z = 6.66 (p < 0.00001), Tau 2 = 0.11, Chi 2 = 6.74, df = 3 (p = 0.08), and I 2 = 55%. Ventilation data from 4 controlled clinical trials involving 4053 COVID-19 patients (486 in the GM-CSF antibody treatment group and 3567 in the control group) were analyzed to assess the overall improvement on ventilation. A total of 326/486 in the GM-CSF antibody treatment group and 2048/3567 patients in control group had improved ventilation, respectively. As shown in Figure 4 , the treatment of GM-CSF antibodies had no effect on improving ventilation in COVID-19 patients (OR = 1.47, 95% CI: 1.19, 1.80). The test for the overall efficacy was Z = 3.67 (p = 0.0002), Tau 2 = 0.00, Chi 2 = 1.97, df = 3 (p = 0.58), and I 2 = 0%. Secondary infections were reported in 4 studies involving 4086 COVID-19 patients; of these, 507 were in the GM-CSF antibody treatment group and 3579 were in the control group. As shown in Figure 5 , The data did not reveal a significant difference in secondary infection between groups (OR = 1.07, 95% CI: 0.87, 1.31). The test for the overall efficacy was Z = 0.62 (p = 0.54), Tau 2 = 0.00, Chi 2 = 1.45, df = 3 (p = 0.69), and I 2 = 0%. The health and economic crisis caused by COVID-19 has become an urgent problem in the international community. Emerging evidence suggests that interleukin-6 (IL-6) is one of the main drivers of the systemic pro-inflammatory response accompanying cytokine release syndrome (CRS) in COVID-19. By activating vascular endothelial growth factor (VEGF) expression and downregulating E-cadherin in endothelial cells through signaling transportation, IL-6 increases vascular permeability and leakage. The GM-CSF antibody blocks IL-6 by binding to its receptor. GM-CSF antibody treatment has emerged as a helpful therapeutic option that has been widely applied in clinical practice. However, the efficacy and safety of GM-CSF antibodies on journals.sagepub.com/home/taj 7 the treatment of COVID-19 remain controversial. We performed this meta-analysis involving 12 studies of 8979 COVID-19 patients. Categorized by the therapeutic strategies, they were divided into the GM-CSF antibody treatment group (n = 2673) and the control group (n = 6306). Our results revealed that GM-CSF antibody treatment significantly reduced mortality but increased the risk of ICU admission. Due to the limited understanding of pathology of COVID-19, the timing of tocilizumab (TCZ) medication should be noted. In the included studies, Martínez-Sanz et al. 19 found that COVID-19 patients with a c-reactive protein (CRP) greater than 150 mg/l can benefited from TCZ, while those with a CRP lower than 150 mg/l cannot. Interestingly, Pereira et al. 11 reported that severe COVID-19 patients with a CRP > 200 mmol/l or haemoglobin A1c (HbA1c) < 1.0 OR d-dimer > 1000, and those who have more concurrent symptoms suffer an increased mortality. Consistent with this, Chilimuri et al. 15 recommended the use of GM-CSF antibodies in severe conditions when the CRP level was > 200 mmol/l. The above findings may have differences due to individual differences and racial differences. In the latest report, GM-CSF antibodies were used to shorten the duration in ICU, which may be related to the decreased ventilation risk. However, the ICU admission rate of COVID-19 patients has been rarely reported. In the included studies, Martínez-Sanz et al. 19 20 believed that an early intervention of GM-CSF antibodies also triggers adverse events in COVID-19 patients. Kimmig et al. 21 and Quartuccio et al. 22 revealed that COVID-19 patients in the GM-CSF antibody group have a higher rate of secondary infection. In our study, we did not obtain a significant difference in secondary infection in COVID-19 patients between groups, which may be attributed that they already have a high incidence of secondary infections. 23 Consistent with previous meta-analyses, unmeasured confounding factors and potential biases in our study should be a concern. Therefore, our primary analysis adopted NOS based on an additional adjustment for propensity score that provided consistent results across these analyses. Although adjustments for potential confounders were performed in our study, some unmeasured confounding factors may exist. In addition, our study may include missing data for some variables and there is potential for inaccuracies in the documentation of electronic health records. Taken together, this meta-analysis provided a systematic comprehensive and updated evaluation of GM-CSF antibody treatment in COVID-19-related clinical outcomes. Otherwise, there are some other factors in this study, such as other drugs, ventilator availability, and vaccines. For example, the effectiveness of Decadron in COVID-19 has been previously reported. 24 So, the synergistic effect or other interactions of these factors (such as Decadron) remains unclear. Therefore, controlled trials are still needed for further verification. Due to the urgent demand for effective treatments for COVID-19, this meta-analysis study comprehensively analyzed the safety and efficacy of GM-CSF antibody treatment, which was identified as being beneficial to COVID-19 patients. Different types of GM-CSF antibodies administration are currently being therapeutically tested in COVID-19 clinical trials. The application of GM-CSF antibodies can reduce respiratory symptoms; however, evidence supporting the function of GM-CSF antibodies in reducing secondary infections of COVID-19 is limited. However, our study had some limitations since some observational studies were included; potential biases of confounding factors could not be excluded. Therefore, more random controlled trials and high-quality literature is required to validate our study. J.G. designed the study. J.G and W.W. performed the systematic literature searching and data extraction. J.D and M.X reviewed the extracted data for analysis. J.G., S.L, and Z.X drafted and revised the manuscript. The authors declare that there is no conflict of interest. Consent statement and ethical approval are not required as the current study was based on published data. Tocilizumab administration in patients with SARS-CoV-2 infection: subcutaneous injection vs intravenous infusion Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: a retrospective cohort study The outcome of hydroxychloroquine in patients treated for COVID-19: systematic review and meta-analysis Feasibility of tocilizumab in ICU patients with COVID-19 The effect of tocilizumab on cytokine release syndrome in COVID-19 patients Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study Tocilizumab for treatment of mechanically ventilated patients with COVID-19 GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched case-control study Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis Tocilizumab in the management of COVID-19: a preliminary report Tocilizumab use in patients with moderate to severe COVID-19: a retrospective cohort study Tocilizumab in patients with severe COVID-19: a retrospective cohort study GM-CSF Neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19 Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicenter cohort study Matched cohort study on the efficacy of tocilizumab in patients with COVID-19 IL-6 Inhibition in critically ill COVID-19 patients is associated with increased secondary infections Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection Zheng-Hao Xu https://orcid.org/0000-0003-0030-4701 Supplemental material for this article is available online.